Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.44 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3046275 | 0.89 | ALDH1A1 (0.50) | ALDH1A1HPGDKDM4EMAPTTSHR | |
| Hydrochloric Acid SCHEMBL3039066 | 0.86 | ALDH1A1 (0.47) | ALDH1A1HPGDKDM4EMAPTTSHR | |
| SCHEMBL3048608 | 0.86 | ALDH1A1 (0.47) | ALDH1A1HPGDKDM4EMAPTTSHR | |
| SCHEMBL3053492 | 0.84 | ADORA2B (0.63) | KMT2AMEN1CHRM4DUSP3 | |
| SCHEMBL3047331 | 0.83 | ALDH1A1 (0.46) | ALDH1A1HPGDKDM4EMAPTTSHR | |
| SCHEMBL3046444 | 0.83 | ALDH1A1 (0.49) | ALDH1A1HPGDKDM4EMAPTTSHR | |
| SCHEMBL3037818 | 0.82 | ALDH1A1 (0.51) | ALDH1A1HPGDKDM4EMAPTTSHR | |
| SCHEMBL3055761 | 0.82 | ALDH1A1 (0.48) | ALDH1A1HPGDKDM4EMAPTTSHR | |
| SCHEMBL3046554 | 0.81 | ALDH1A1 (0.55) | ALDH1A1HPGDKDM4EMAPTTSHR | |
| SCHEMBL3037936 | 0.81 | KMT2A (0.45) | ALDH1A1HPGDKDM4EMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075959-A1 | BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS | ALANINE ALEXANDER | 2010-03-25 | — | — | US | disclosed |
| US-20080125419-A1 | BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS | ALANINE ALEXANDER | 2008-05-29 | — | — | US | disclosed |
| US-20080108809-A1 | BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS | ALANINE ALEXANDER | 2008-05-08 | — | — | US | disclosed |
| US-7317007-B2 | Benzothiazole derivatives with activity as adenosine receptor ligands | HOFFMANN-LA ROCHE INC. (US) | 2008-01-08 | — | — | US | disclosed |
| EP-1797878-A2 | Benzothiazole derivatives | F. Hoffmann-La Roche AG (CH) | 2007-06-20 | — | — | EP | disclosed |
| US-20060003986-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ALANINE ALEXANDER | 2006-01-05 | — | — | US | disclosed |
| US-6963000-B2 | Benzothiazole derivatives with activity as adenosine receptor ligands | HOFFMAN-LA ROCHE INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-20050026906-A1 | Benzothiazole derivatives with actitvity as adenosine receptor ligands | ALANINE ALEXANDER (FR) | 2005-02-03 | — | — | US | disclosed |
| US-6835732-B2 | Modulation of the adenosine A2A receptor; cardioprotective agents; antiischemic agents; antihypoxia agents; central nervous system disorders, Alzheimer's disease, Parkinson's disease, anxiolytic agents; antidepressants; analgesics | HOFFMAN-LA ROCHE INC. | 2004-12-28 | — | — | US | disclosed |
| US-20030176695-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ALANINE ALEXANDER (FR) | 2003-09-18 | — | — | US | disclosed |
| US-20030125318-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ALANINE ALEXANDER (FR) | 2003-07-03 | — | — | US | disclosed |
| US-20020045615-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | F.HOFFMANN-LA ROCHE AG (CH) | 2002-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060003986-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ADORA2A, ADORA1, ADORA3 | ALDH1A1 383/4885HPGD 2398/4885KDM4E 3849/4885 |
| US-20080108809-A1 | BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS | ADORA2A, ADORA1, ADORA3 | ALDH1A1 383/4885HPGD 2398/4885KDM4E 3849/4885 |
| US-20080125419-A1 | BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS | ADORA2A, ADORA1, ADORA3 | ALDH1A1 473/4885HPGD 2488/4885KDM4E 3863/4885 |
| US-20030125318-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ADORA2A, ADORA1, ADORA3 | ALDH1A1 383/4885HPGD 2398/4885KDM4E 3849/4885 |
| US-20030176695-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ADORA2A, ADORA1, ADORA3 | ALDH1A1 383/4885HPGD 2398/4885KDM4E 3849/4885 |
| US-20050026906-A1 | Benzothiazole derivatives with actitvity as adenosine receptor ligands | ADORA2A, ADORA1, ADORA3 | ALDH1A1 452/4885HPGD 2538/4885KDM4E 4127/4885 |
| US-20100075959-A1 | BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS | ADORA2A, ADORA1, ADORA3 | ALDH1A1 473/4885HPGD 2488/4885KDM4E 3863/4885 |
| US-20020045615-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ADORA2A, ADORA1, ADORA3 | ALDH1A1 383/4885HPGD 2398/4885KDM4E 3849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.